The Sheel Biotech Limited IPO is an upcoming SME IPO on the NSE Emerge platform, bringing attention to India’s growing plant tissue culture and organic farming industry. Incorporated in 1991, Sheel Biotech is engaged in tissue culture plants, organic farming, landscaping, greenhouses, and farmer support services.
With over three decades of experience and contributions to sustainable farming practices, Sheel Biotech aims to use IPO proceeds to expand capacity and meet working capital needs.
This article covers the Sheel Biotech IPO details, price band, allotment, financials, industry outlook, risks, and FAQs for investors.
Sheel Biotech IPO – Event Schedule
| Event | Date |
|---|---|
| Anchor Investor Bidding Date | September 29, 2025 |
| IPO Open Date | September 30, 2025 |
| IPO Close Date | October 3, 2025 |
| Allotment Finalization | October 6, 2025 (Tentative) |
| Refunds / Unblocking of Funds | October 7, 2025 (Tentative) |
| Credit of Shares to Demat | October 7, 2025 (Tentative) |
| Listing Date | October 9, 2025 (Tentative) |
| UPI Mandate Cut-off | 5 PM, October 3, 2025 |
Sheel Biotech IPO – Structure and Key Details
- Company: Sheel Biotech Limited
- Industry: Tissue Culture & Organic Farming
- Issue Type: Book Built IPO
- Fresh Issue: 54,00,000 equity shares of face value ₹10 each
- Offer for Sale (OFS): Nil
- Post-Issue Holding: Issue will constitute 26.53% of post-issue equity capital
- Book Running Lead Manager (BRLM): Narnolia Financial Services Limited
- Registrar: Skyline Financial Services Pvt. Ltd.
- Listing At: NSE Emerge
Company Overview
Sheel Biotech, headquartered in New Delhi, was incorporated in 1991 as Sheel Biotech Pvt Ltd and converted into a public company in 1992.
Business Model:
- Tissue Culture: Large-scale propagation of high-yield, disease-free plants for crops, fruits, and ornamental plants.
- Organic Farming: Development and promotion of biofertilizers, biopesticides, and sustainable practices.
- Greenhouses & Landscaping: Manufacturing greenhouses and providing landscaping services.
- Farmer Support: Training through Farmer Producer Organizations (FPOs).
Promoters:
Dr. Satya Narayan Chandak, Dr. Sanjay Chandak, Mr. Divye Chandak, Mrs. Mini Chadha, and family HUF entities.
Also read: The Business of Fun – An Industry Report
Sheel Biotech IPO – Financial Performance
From the restated consolidated financials (₹ in Crores):
| Particulars | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue from Operations | ₹47.11 Cr | ₹68.84 Cr | ₹90.25 Cr |
| EBITDA | ₹4.39 Cr | ₹6.93 Cr | ₹8.11 Cr |
| Net Profit (PAT) | ₹2.94 Cr | ₹4.81 Cr | ₹6.58 Cr |
| PAT Margin | 6.2% | 7.0% | 7.3% |
| ROE | 16.1% | 19.3% | 21.5% |
| ROCE | 17.8% | 20.4% | 22.0% |
Highlights:
- Revenue doubled from FY23 to FY25.
- PAT grew more than 120% in 3 years.
- Healthy return ratios (ROE > 20% in FY25).
Objects of the Issue
Net proceeds from the IPO will be used for:
- Capital expenditure – ₹9.11 Cr
- Working capital requirements – ₹11.58 Cr
- General corporate purposes – balance proceeds
Industry Outlook
The Indian tissue culture and plant biotechnology industry is poised for rapid growth:
- Market Drivers: Demand for disease-free, high-yield crops, government push for organic farming, and rising export demand.
- Technological Advancements: Automation, bioreactors, and advanced genetics enabling higher efficiency.
- Sustainability Push: Shift toward organic farming and bio-based inputs.
Sheel Biotech, with tissue culture, organics, and farmer support services, is aligned with India’s sustainable agriculture goals.
Key Risks
- SME Listing: Lower liquidity and higher volatility.
- Agriculture Dependence: Growth tied to monsoon, farm income, and crop cycles.
- Competition: Faces established biotech and agro players.
- Working Capital Intensive: Requires significant investment in operations.
- Scale: Mid-sized operations compared to larger biotech peers.
Sheel Biotech IPO Allotment and Application
- Registrar: Skyline Financial Services Pvt. Ltd.
- Investors can check allotment on Skyline’s IPO portal using PAN, DP/Client ID, or Application Number.
- Retail investors must apply via UPI/ASBA before 5 PM, October 3, 2025.
Investor Takeaways
Strengths:
- Strong growth in revenue and profit.
- Focus on sustainable, high-demand segments (tissue culture, organics).
- IPO is 100% fresh issue – funds will support expansion.
Risks:
- Agriculture-linked cyclicality.
- SME platform listing risks.
- High competition and working capital needs.
Conclusion
The Sheel Biotech IPO provides exposure to India’s growing tissue culture and organic farming industry. With strong financial growth, healthy margins, and use of funds for expansion and working capital, the company has positioned itself for growth.
However, investors should consider agriculture-linked cyclicality and SME platform risks before applying. For those bullish on India’s sustainable farming and biotechnology space, Sheel Biotech IPO is worth exploring.
Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.
© 2025 — Tradejini. All Rights Reserved.
